Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 28;12(11):1781.
doi: 10.3390/jpm12111781.

The Australian Reproductive Genetic Carrier Screening Project (Mackenzie's Mission): Design and Implementation

Affiliations

The Australian Reproductive Genetic Carrier Screening Project (Mackenzie's Mission): Design and Implementation

Alison D Archibald et al. J Pers Med. .

Abstract

Reproductive genetic carrier screening (RGCS) provides people with information about their chance of having children with autosomal recessive or X-linked genetic conditions, enabling informed reproductive decision-making. RGCS is recommended to be offered to all couples during preconception or in early pregnancy. However, cost and a lack of awareness may prevent access. To address this, the Australian Government funded Mackenzie’s Mission—the Australian Reproductive Genetic Carrier Screening Project. Mackenzie’s Mission aims to assess the acceptability and feasibility of an easily accessible RGCS program, provided free of charge to the participant. In study Phase 1, implementation needs were mapped, and key study elements were developed. In Phase 2, RGCS is being offered by healthcare providers educated by the study team. Reproductive couples who provide consent are screened for over 1200 genes associated with >750 serious, childhood-onset genetic conditions. Those with an increased chance result are provided comprehensive genetic counseling support. Reproductive couples, recruiting healthcare providers, and study team members are also invited to complete surveys and/or interviews. In Phase 3, a mixed-methods analysis will be undertaken to assess the program outcomes, psychosocial implications and implementation considerations alongside an ongoing bioethical analysis and a health economic evaluation. Findings will inform the implementation of an ethically robust RGCS program.

Keywords: bioethics; health economics; implementation science; psychosocial outcomes; reproductive genetic carrier screening.

PubMed Disclaimer

Conflict of interest statement

Alison D. Archibald, Martin B. Delatycki, Anaita Kanga-Parabia, Sebastian Lunke and Justine E. Marum are employed by Victorian Clinical Genetics Services, a not-for-profit RGCS provider. Edwin P. Kirk is employed by NSW Health Pathology, who provide RGCS on a fee-for-service basis, and Genea, a fertility company that refers patients for RGCS. Corrina C. Cliffe is also an employee of NSW Health Pathology. Tristan Hardy is employed by Monash IVF Group, who provide RGCS on a fee-for-service basis. Leslie Burnett did not have any competing interests at the time of his contribution to the MM study, but is now employed by Invitae Australia, who provide RGCS on a fee-for-service basis.

Figures

Figure 2
Figure 2
Mackenzie’s Mission’s study design showing the implementation phases.
Figure 1
Figure 1
Mackenzie’s Mission’s governance structure.
Figure 3
Figure 3
Data collection timepoints for people offered reproductive genetic carrier screening in the Mackenzie’s Mission study.
Figure 4
Figure 4
Laboratory testing and management of results in the Mackenzie’s Mission study.

References

    1. Delatycki M.B., Laing N., Moore S., Emery J., Archibald A.D., Massie J., Kirk E. Preconception and antenatal carrier screening for genetic conditions: ‘The critical role of general practitioners’. Aust. J. Gen. Pract. 2019;48:106–110. doi: 10.31128/AJGP-10-18-4725. - DOI - PubMed
    1. Delatycki M.B., Alkuraya F., Archibald A.D., Castellani C., Cornel M., Grody W.W., Henneman L., Ioannides A.S., Kirk E., Laing N., et al. International perspectives on the implementation of reproductive carrier screening. Prenat. Diagn. 2020;40:301–310. doi: 10.1002/pd.5611. - DOI - PubMed
    1. Beauchamp K.A., Johansen Taber K.A., Muzzey D. Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen. Genet. Med. 2019;21:1948–1957. doi: 10.1038/s41436-019-0455-8. - DOI - PMC - PubMed
    1. Ropers H.H. On the future of genetic risk assessment. J. Community Genet. 2012;3:229–236. doi: 10.1007/s12687-012-0092-2. - DOI - PMC - PubMed
    1. Dive L., Newson A.J. Ethics of reproductive genetic carrier screening: From the clinic to the population. Public Health Ethics. 2021;14:202–217. doi: 10.1093/phe/phab017. - DOI - PMC - PubMed

LinkOut - more resources